Normally, interactions between receptors like PD-1 on T-cells and their ligand, such as PD-L1 on tumor cells, create an “immune checkpoint” that suppresses T-cell activity, preventing immune-mediated destruction of cancer cells [6]. This evidence concerns the gene PDCD1 and neoplasm.